NZ754676A - Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta - Google Patents
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaInfo
- Publication number
- NZ754676A NZ754676A NZ754676A NZ75467617A NZ754676A NZ 754676 A NZ754676 A NZ 754676A NZ 754676 A NZ754676 A NZ 754676A NZ 75467617 A NZ75467617 A NZ 75467617A NZ 754676 A NZ754676 A NZ 754676A
- Authority
- NZ
- New Zealand
- Prior art keywords
- osteogenesis imperfecta
- patient
- treatment
- sclerostin antibody
- effective amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437353P | 2016-12-21 | 2016-12-21 | |
| PCT/GB2017/053850 WO2018115880A1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ754676A true NZ754676A (en) | 2023-06-30 |
Family
ID=60915566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ754676A NZ754676A (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20200179509A1 (https=) |
| EP (2) | EP3478719B3 (https=) |
| JP (3) | JP7050335B2 (https=) |
| KR (3) | KR20190096409A (https=) |
| CN (2) | CN110325548B (https=) |
| AU (1) | AU2017381433B2 (https=) |
| BR (1) | BR112019012731A2 (https=) |
| CA (1) | CA3047221A1 (https=) |
| CL (1) | CL2019001749A1 (https=) |
| CY (1) | CY1124238T1 (https=) |
| DK (1) | DK3478719T6 (https=) |
| ES (1) | ES2862922T7 (https=) |
| FI (1) | FI3478719T6 (https=) |
| HR (1) | HRP20210207T4 (https=) |
| HU (1) | HUE053436T2 (https=) |
| IL (1) | IL267430B2 (https=) |
| LT (1) | LT3478719T (https=) |
| MX (1) | MX2019007161A (https=) |
| NZ (1) | NZ754676A (https=) |
| PL (1) | PL3478719T6 (https=) |
| PT (1) | PT3478719T (https=) |
| SI (1) | SI3478719T2 (https=) |
| WO (1) | WO2018115880A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019007161A (es) * | 2016-12-21 | 2020-02-12 | Mereo Biopharma 3 Ltd | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3774879B1 (en) | 2018-03-30 | 2026-01-28 | Amgen Inc. | C-terminal antibody variants |
| AU2019289222B2 (en) | 2018-06-18 | 2023-07-13 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| KR102472582B1 (ko) * | 2020-08-20 | 2022-11-30 | 한림대학교 산학협력단 | 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법 |
| AU2022357544A1 (en) * | 2021-09-30 | 2024-04-11 | Mereo Biopharma 3 Limited | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| ATE481487T1 (de) | 1998-11-27 | 2010-10-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| MY149129A (en) * | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| EP2558106A1 (en) * | 2010-04-16 | 2013-02-20 | Novartis AG | Methods and compositions for improving implant osseointegration |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| MX2019007161A (es) * | 2016-12-21 | 2020-02-12 | Mereo Biopharma 3 Ltd | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. |
| US10961305B2 (en) * | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
-
2017
- 2017-12-21 MX MX2019007161A patent/MX2019007161A/es unknown
- 2017-12-21 CN CN201780087087.2A patent/CN110325548B/zh active Active
- 2017-12-21 JP JP2019533586A patent/JP7050335B2/ja active Active
- 2017-12-21 AU AU2017381433A patent/AU2017381433B2/en active Active
- 2017-12-21 NZ NZ754676A patent/NZ754676A/en unknown
- 2017-12-21 CN CN202311429543.0A patent/CN117442720A/zh active Pending
- 2017-12-21 KR KR1020197021162A patent/KR20190096409A/ko not_active Ceased
- 2017-12-21 FI FIEP17823190.8T patent/FI3478719T6/fi active
- 2017-12-21 EP EP17823190.8A patent/EP3478719B3/en active Active
- 2017-12-21 PT PT178231908T patent/PT3478719T/pt unknown
- 2017-12-21 WO PCT/GB2017/053850 patent/WO2018115880A1/en not_active Ceased
- 2017-12-21 LT LTEP17823190.8T patent/LT3478719T/lt unknown
- 2017-12-21 KR KR1020247023410A patent/KR20240113615A/ko not_active Ceased
- 2017-12-21 US US16/469,915 patent/US20200179509A1/en not_active Abandoned
- 2017-12-21 EP EP21152251.1A patent/EP3868780A1/en active Pending
- 2017-12-21 IL IL267430A patent/IL267430B2/en unknown
- 2017-12-21 KR KR1020227011791A patent/KR20220051269A/ko not_active Ceased
- 2017-12-21 BR BR112019012731-3A patent/BR112019012731A2/pt unknown
- 2017-12-21 ES ES17823190T patent/ES2862922T7/es active Active
- 2017-12-21 DK DK17823190.8T patent/DK3478719T6/da active
- 2017-12-21 HR HRP20210207TT patent/HRP20210207T4/hr unknown
- 2017-12-21 SI SI201730627T patent/SI3478719T2/sl unknown
- 2017-12-21 PL PL17823190.8T patent/PL3478719T6/pl unknown
- 2017-12-21 HU HUE17823190A patent/HUE053436T2/hu unknown
- 2017-12-21 CA CA3047221A patent/CA3047221A1/en active Pending
-
2019
- 2019-06-21 CL CL2019001749A patent/CL2019001749A1/es unknown
-
2020
- 2020-01-02 US US16/733,144 patent/US20200123242A1/en not_active Abandoned
- 2020-12-30 US US17/138,691 patent/US20210253684A1/en not_active Abandoned
-
2021
- 2021-04-02 CY CY20211100286T patent/CY1124238T1/el unknown
- 2021-12-10 JP JP2021200994A patent/JP2022046529A/ja active Pending
-
2023
- 2023-04-07 US US18/297,280 patent/US20230365669A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/669,337 patent/US20240400666A1/en active Pending
- 2024-10-11 JP JP2024179475A patent/JP2025020150A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ754676A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
| MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
| MX2019009117A (es) | Anticuerpos anti alfa-sinucleina y usos de los mismos. | |
| NZ728636A (en) | Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor | |
| PH12019500261B1 (en) | Methods for treating osteogenesis imperfecta | |
| MX2023004333A (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. | |
| PH12017501522A1 (en) | Antibodies to tau and uses thereof | |
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MY177915A (en) | Il-21 antibodies | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| EP4530296A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| PH12018500445B1 (en) | Use of anti-cd40 antibodies for treatment of lupus nephritis | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| ZA202205813B (en) | Trpv1 epitopes and antibodies | |
| MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
| MX2023003723A (es) | Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico. | |
| MY207627A (en) | Methods of treating psoriasis | |
| EA201990559A1 (ru) | Комбинированная терапия | |
| EA202092640A1 (ru) | Способы и композиции для лечения хронической крапивницы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2024 BY MAXVAL GROUP INC. Effective date: 20231205 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2025 BY MAXVAL GROUP INC. Effective date: 20241210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2026 BY MAXVAL GROUP INC. Effective date: 20251209 |